Immunization with an antigen identified by cytokine tumor vaccine-assisted SEREX (CAS) suppressed growth of the rat 9L glioma in Vivo

Cancer Research

Volumn 61, Issue 6, 2001, Pages 2625-2631

  Okada, Hideho ^a,b   Attanucci, Jason ^a   Giezeman Smits, Katinka M ^a   Brissette Storkus, Cynthia ^b   Fellows, Wendy K ^a   Gambotto, Andrea ^b   Pollack, Ian F ^a   Pogue Geile, Kay ^b   Lotze, Michael T ^b   Bozik, Michael E ^c   Chambers, William H ^b  

^a UNIVERSITY OF PITTSBURGH CANCER INSTITUTE   (United States)

^b UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^c BRISTOL MYERS SQUIBB   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CALCYCLIN; COMPLEMENTARY DNA; CYTOKINE; INTERLEUKIN 4; RECOMBINANT DNA; TUMOR ANTIGEN; TUMOR REJECTION ANTIGEN; TUMOR VACCINE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY TITER; ANTINEOPLASTIC ACTIVITY; ARTICLE; B LYMPHOCYTE; CANCER IMMUNIZATION; CONTROLLED STUDY; DNA LIBRARY; GENE THERAPY; GLIOMA; GROWTH INHIBITION; HUMORAL IMMUNITY; IMMUNE RESPONSE; IN VIVO STUDY; LYMPHOCYTE ACTIVATION; NONHUMAN; NORTHERN BLOTTING; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; SEROLOGY; TUMOR IMMUNITY;

ANIMALS; ANTIBODIES, NEOPLASM; ANTIGENS, NEOPLASM; BASE SEQUENCE; CANCER VACCINES; CELL CYCLE PROTEINS; CELL DIVISION; DNA, COMPLEMENTARY; DNA-BINDING PROTEINS; GLIOSARCOMA; IMMUNOGLOBULIN ISOTYPES; IMMUNOGLOBULIN SWITCH REGION; INTERLEUKIN-4; MALE; MICE; MOLECULAR SEQUENCE DATA; RATS; RATS, INBRED F344; S100 PROTEINS; SENSITIVITY AND SPECIFICITY; SEROLOGIC TESTS; TH2 CELLS; TUMOR CELLS, CULTURED; VACCINES, DNA;

EID: 0035866820     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (58)

1. Relapse in the central nervous system in melanoma patients successfully treated with biomodulators
2. Immunology of central nervous system tumors
3. Growth of P511 mastocytoma cells in BALB/c mouse brain elicits CTL response without tumor elimination
4. Immune defects observed in patients with primary malignant brain tumors
5. Multiple sclerosis: Comparison of the human T-cell response to S100 β and myelin basic protein reveal parallels to rat experimental autoimmune panencephalitis
6. Immunopathogenic mechanisms in experimental allergic encephalomyelitis
7. Effective cytokine gene therapy against an intracranial glioma using a retrovirally transduced IL-4 plus HSV-TK tumor vaccine
8. + T cells by interleukin-4-transfected 9L gliosarcoma is essential for protective immunity
9. Gene therapy of malignant gliomas: A Phase I study of IL4HSV-TK gene-modified autologous tumor to elicit an immune response
10. Induction of lethal experimental allergic encephalomyelitis in non-human primates and guinea pigs with human glioblastoma multiforme tissue
11. Immunologie et immunotherapie des tumeurs cerebrales
12. Glioblastoma multiforme: A controlled trial to assess the value of specific active immunotherapy in patients treated by radical surgery and radiotherapy
13. Immunobiology of primary intracranial tumors. Part 7: Active immunization of patients with anaplastic human glioma cells: A pilot study
14. Bone marrow-derived dendritic cells pulsed with a tumor-specific peptide elicit effective anti-tumor immunity against intracranial neoplasms
15. Human neoplasms elicit multiple specific immune responses in the autologous host
16. Serological identification of human tumor antigens
17. New paths in human cancer serology
18. Tumor antigens recognized by T-lymphocytes
19. Cancer vaccines based on the identification of genes encoding cancer regression antigens
20. A testicular antigen aberrantly expressed in human cancers detected by autologous antibody screening
21. Simultaneous humoral and cellular immune response against cancer-testis antigen NY-ESO-1: Definition of human histocompatibility leukocyte antigen (HLA)-A2-binding peptide epitopes
22. Identification of NY-ESO-1 epitopes presented by human histocompatibility antigen (HLA)-DRB4*0101-0103 and recognized by CD4(+) T lymphocytes of patients with NY-ESO-1-expressing melanoma
23. Detection and monitoring of serum p53 antibodies in patients with colorectal cancer
24. Prognostic significance of circulating P53 antibodies in patients undergoing surgery for locoregional breast cancer
25. Serum p53 antibodies as early markers of lung cancer
26. Absense of p53 autoantibodies in sera from glioma patients
27. The p53 gene and its role in human brain tumors
28. The failure of current immunotherapy for malignant glioma. Tumor-derived TGF-β, T-cell apoptosis, and the immune privilege of the brain
29. Murine interleukin-4 displays potent anti-tumor activity in vivo
30. An efficient Th2-type memory follows CD8+ lymphocyte-driven and eosinophil-mediated rejection of a spontaneous mouse mammary adenocarcinoma engineered to release IL-4
31. Treatment of established renal cancer by tumor cells engineered to secrete interleukin-4
32. T-cell dependent intracerebral tumor regression of a 9L gliosarcoma expressing mIL-4 in a syngeneic host
33. B cell stimulatory factor I (interleukin 4) is a potent costimulant for normal resting T lymphocytes
34. Interleukin 4 promotes the growth of tumor-infiltrating lymphocytes cytotoxic for human autologous melanoma
35. Interleukin-4 induces adherence of human eosinophils and basophils but not neutrophils to endothelium. Activation with expression of VCAM-1
36. Recombinant interleukin-4 promotes the growth of human T-cells
37. Interleukin-4: Signalling mechanism and control of T-cell differentiation
38. Bone marrow-derived dendritic cells pulsed with synthetic tumour peptides elicit protective and therapeutic antitumor immunity
39. The influence of interleukin (IL)-4, IL-13, and Flt3 ligand on human dendritic cell differentiation from cord blood CD34+ progenitor cells
40. Increased expression of Ia antigens on resting B cells
41. Regulation of IgG1 and IgE production by interleukin 4
42. Interleukin-4
43. Interleukin-4 inhibits the proliferation but not the differentiation of activated human B cells in response to interleukin-2
44. Genomic sequencing
45. Quantitative molecular hybridization on nylon membranes
46. Differential regulation of IgG1 and IgE synthesis by interleukin 4
47. Alteration of gene expression in rat mammary tumors induced by N-methyl-N-nitrosourea
48. Expression of calcyclin in human melanocytic lesions
49. Cloning of a cDNA for a T cell produced molecule with a putative immune regulatory role
50. MIDA1, a protein associated with Id, regulates cell growth
51. Expression pattern of S100 calcium-binding proteins in human tumors
52. Modulation of S-100 genes response to growth conditions in human epithelial tumor cells
53. MIDA1, an Id-associating protein, has two distinct DNA binding activities that are converted by the association with Id1: A novel function of Id protein
54. The SSX-2 gene, which is involved in the t(X;18) translocation of synovial sarcomas, codes for the human tumor antigen HOM-MEL-40
55. Identification of multiple cancer/testis antigens by allogeneic antibody screening of a melanoma cell line library
56. The CD40 ligand, gp39, is defective in activated T cells from patients with X-linked hyper-IgM syndrome
57. + cell-mediated immunity against tumors located in the "immunologically privileged" central nervous system
58. Specific T helper cell requirement for optimal induction of cytotoxic T lymphocytes against major histocompatibility complex class II negative tumors